Articles From: Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients to Oncothyreon to Present at Upcoming Investor Conferences


2015/2/9
Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients Canada NewsWire CALGARY , Feb.
Sign-up for Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients investment picks
2015/2/17
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer Canada NewsWire CALGARY , Feb.
Sign-up for Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer investment picks
2014/12/1
REDWOOD CITY, Calif., Dec.
Sign-up for OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer investment picks
2015/1/5
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody investment picks
2015/1/15
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial in Solid Tumors investment picks
2015/2/4
REDWOOD CITY, Calif., Feb.
Sign-up for OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer investment picks
2015/1/7
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
2015/1/28
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences in February investment picks
2015/1/12
Begins 2015 with $232 Million in Cash Potential Milestones from Existing Partnerships in 2015/2016 Projected at Over $150 Million REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance investment picks
2015/1/16
Median Overall Survival of 14.6 Months in Tumor Notch3 High Patients and 11.6 Months in All Patients REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic Cancer at the 2015 Gastrointestinal Cancer Symposium investment picks
2015/1/13
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed to Present Clinical Data and Biomarker Analysis for Tarextumab at the 2015 Gastrointestinal Cancer Symposium investment picks
2015/2/2
Clarity of the design of Phase 3 global replication trial of IV rigosertib in HR-MDS Updates on development programs for oral rigosertib as a single agent and in combination with azacitidine; additional data expected for both in 2015 NEWTOWN, Pa., Feb.
Sign-up for Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs) investment picks
2014/12/7
NEWTOWN, Pa., Dec.
Sign-up for Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting investment picks
2015/1/12
NEWTOWN, Pa., Jan.
Sign-up for Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer investment picks
2014/12/5
NEWTOWN, Pa., Dec.
Sign-up for Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014 investment picks
2015/1/30
NEWTOWN, Pa., Jan.
Sign-up for Onconova Therapeutics, Inc. to Present at Upcoming Investor Conferences in February investment picks
2014/12/8
OncoSec Medical Inc. (OTCQB: ONCS ), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014.
Sign-up for OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015 investment picks
2015/2/18
OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS ), a company developing DNA-based intratumoral cancer immunotherapies, and Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.
Sign-up for OncoSec Medical Inc. and Heat Biologics, Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms investment picks
2014/12/12
SEATTLE, Dec.
Sign-up for Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380 investment picks
2014/12/12
SEATTLE, Dec.
Sign-up for Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium investment picks
2015/2/5
SEATTLE, Feb.
Sign-up for Oncothyreon Announces Proposed Public Offerings investment picks
2015/2/6
SEATTLE, Feb.
Sign-up for Oncothyreon Prices $22 Million Concurrent Public Offerings of Common Stock and Preferred Stock investment picks
2015/2/17
SEATTLE, Feb.
Sign-up for Oncothyreon to Present at Upcoming Investor Conferences investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients to Oncothyreon to Present at Upcoming Investor Conferences
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent